Abstract:
|
Active comparator studies are becoming increasingly important in the medical affairs world for presenting evidence of added benefit from a new compound introduced in a crowded market with existing therapies for a particular disease. Also, regulatory agencies require phase 3 studies to include a reference arm when other therapies exist in the market. Lack of solid phase 2 evidence and cost limitations often restrict statisticians to design studies that provide head-to-head comparison with an active reference in a phase 3 study design. In this session, we would like to discuss the pros and cons of including a mere reference arm in a phase 3 study as well as the challenges in designing a head-to-head active comparator study in phase 3 or 4.
|